Abstracts tagged "Fatigue"

Abstract Number: 0854 • ACR Convergence 2021
Confirmatory Factor Analysis of the Fatigue Assessment Instrument and Fatigue Severity Scale in Systemic Sclerosis
Alyssa Choi¹, Chelsea Rapoport², Erin Merz³, Marka Lyons⁴, Maureen Mayes⁵, Shervin Assassi⁶ and Vanessa Malcarne⁷, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, La Jolla, CA, ³Department of Psychology, California State University, Dominguez Hills, Carson, CA, ⁴Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶University of Texas McGovern Medical School at Houston, Houston, TX, ⁷SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA
Background/Purpose: Fatigue is a prevalent, debilitating symptom across chronic diseases that is difficult to treat and negatively impacts patients' quality of life. Patients with rheumatologic…
Abstract Number: 0860 • ACR Convergence 2021
Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis
Laura Kimble¹, Arezou Khosroshahi¹, Glenna Brewster¹, Nicole Carlson¹, Ronald Eldridge¹ and Elizabeth Corwin², ¹Emory University, Atlanta, GA, ²Columbia University, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) occurs predominantly in women and Black women have disproportionately poorer health outcomes across the trajectory of their disease compared to…
Abstract Number: 1150 • ACR Convergence 2021
Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)
Janet Poole¹, Deirdre Connolly² and Kristine Carandang³, ¹University of New Mexico, Albuquerque, NM, ²Trinity Centre for Health Sciences, Dublin, Ireland, ³Independent, San Diego, CA
Background/Purpose: Fatigue remains an understudied symptom of systemic sclerosis (SSc). For other diagnoses, increasing the use of energy conservation strategies, especially pacing. has been associated…
Abstract Number: 1235 • ACR Convergence 2021
Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Bruno Fautrel¹, Bochao Jia², Jianmin Wu³, Ju Ji², Julie Birt², Ewa Haladyj² and Tsutomu Takeuchi⁴, ¹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianaplolis, IN, ⁴Div. Rheumatology, Keio University, Tokyo, Japan
Background/Purpose: Fatigue is very common in rheumatoid arthritis (RA) and impairs patient quality of life. Baricitinib (BARI) improved fatigue, pain and other patient-reported outcomes (PROs)…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 1847 • ACR Convergence 2020
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Hope Rainey¹, Kristy Bell¹, Violeta Rus², Daniel Wallace³, Claire Dykas¹, Mary Mora¹, Maggy Comberg¹ and Peter Lipsky¹, ¹AMPEL BioSolutions LLC., Charlottesville, VA, ²University of Maryland School of Medicine, Baltimore, MD, ³Cedars-Sinai Medical Center/UCLA, Los Angeles, CA
Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…
Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Frank Behrens¹, Ulrich Prothmann², Thilo Klopsch³, Ann-Dörthe Holst⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Saarland, Germany, ³Rheumatological Practice, Neubrandenburg, Mecklenburg-Vorpommern, Germany, ⁴Specialist Practice for General Medicine incl. Rheumatology and Acupuncture, Ludwigslust, Mecklenburg-Vorpommern, Germany, ⁵Pfizer Pharma GmbH, Berlin, Berlin, Germany
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…
Abstract Number: 1081 • ACR Convergence 2020
Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
Valérie Leclair¹, Brett Thombs², Mianbo Wang³, Evelyne Vinet⁴, Alexandra Albert⁵ and Marie Hudson⁶, ¹Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ²Department of Psychology, McGill University, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada; Department of Medicine, Université Laval, Québec, QC, Canada., Neuville, Canada, ⁶Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Patient-reported outcomes (PROs) are increasingly used in rheumatology. Such outcomes are under-reported in autoimmune inflammatory myopathies (AIM) especially in incident cohorts. The objective of…
Abstract Number: 1089 • ACR Convergence 2020
Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus
Jorge Gamboa¹, Daniel Carranza Leon¹, Rachelle Crescenzi¹, Adriana Marton², Annette Oeser¹, Cecilia Chung¹, Jens Titze², Michelle Ormseth¹ and C. Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke NUS Medical School, Singapore, Singapore
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have reduced physical activity and frequently complain of fatigue. Exercise reduces fatigue in patients with SLE; however, the…
Abstract Number: 1134 • ACR Convergence 2020
Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases
Katherine Wysham¹, Joshua Baker², Kristin Wipfler³, Sarah Lieber⁴, Sebastian Sattui⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹VA Puget Sound/University of Washington, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Hospital for Special Surgery, New York, NY, ⁵University of California, San Francisco, Novato, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Frailty is associated with poor health outcomes in the general population, and recent studies have highlighted its importance in rheumatic musculoskeletal diseases (RMDs). Prior…
Abstract Number: 1215 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
David Walker¹, Tsutomu Takeuchi², Beatrix Bartok³, Shangbang Rao³, I-Heng Lee⁴, Robin Besuyen⁵, Jacques-Eric Gottenberg⁶ and Mark Genovese³, ¹Northumbria Healthcare Trust, North Shields, United Kingdom, ²Keio Univ School of Medicine, Tokyo, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Strasbourg University Hospital, Strasbourg, France
Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…
Abstract Number: 1218 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Alan Kivitz¹, Yoshiya Tanaka², Susan Lee³, Lei Ye³, Hao Hu³, Robin Besuyen⁴ and Bernard Combe⁵, ¹Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵University of Montpellier, Montpellier, France
Background/Purpose: In the FINCH 1 study, filgotinib (FIL)—an oral, potent, selective JAK1 inhibitor—plus methotrexate (MTX) provided significant improvements in signs and symptoms of rheumatoid arthritis…
Abstract Number: 1242 • ACR Convergence 2020
Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
Ana Pinto¹, Sara Piva², Alexia Vieira³, Samantha Gomes³, Aline Rocha⁴, Daniela Tavares³, Marcia Santana³, Cristiane Carlesso⁵, Adagmar Andriolo³, Fania Santos⁶, Felipe Fregni⁷ and Virginia Trevisani³, ¹Universidade Federal do Amapa, Sao Paulo, Brazil, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁴Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁵University of Pittsburgh, Pittsburgh, ⁶Universidade Federal de Sao Paulo, Sao Paulo, Saint Helena, ⁷Harvard Medical School, Cambridge, MA
Background/Purpose: Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). We aimed to assess…
Abstract Number: 1243 • ACR Convergence 2020
Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression
Roeland Prak¹, Suzanne Arends², Greetje van Zuiden¹, Frans Kroese¹, Hendrika Bootsma¹ and Inge Zijdewind¹, ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Fatigue is a major complaint in autoimmune diseases including primary Sjögren’s syndrome (pSS). For many pSS patients, fatigue is their most dominant and disabling…
Abstract Number: 1314 • ACR Convergence 2020
Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
Jessica Walsh¹, Kaleb Michaud², Elizabeth Holdsworth³, Steven Peterson⁴, Nicola Booth³, Sophie Meakin³, Soumya Chakravarty⁵, James Piercy³ and Alexis Ogdie⁶, ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²University of Nebraska Medical Center, Omaha, NE, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Fatigue is an important aspect of PsA for patients. Understanding the impact of fatigue on patient reported outcomes is important for effective management of…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].